Cargando…

Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis

BACKGROUND: Controversy exists about the most appropriate treatment for high-risk superficial (stage T1; grade G3) bladder cancer. Immediate cystectomy offers the best chance for survival but may be associated with an impaired quality of life compared with conservative therapy. We estimated life exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulkarni, Girish S, Finelli, Antonio, Fleshner, Neil E, Jewett, Michael A. S, Lopushinsky, Steven R, Alibhai, Shabbir M. H
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1989749/ https://www.ncbi.nlm.nih.gov/pubmed/17896857 http://dx.doi.org/10.1371/journal.pmed.0040284

Ejemplares similares

Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?
por: Alkhateeb, Sultan Saud, et al.
Publicado: (2010)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy
por: Bhindi, Bimal, et al.
Publicado: (2016)

Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma
por: Gedye, Craig, et al.
Publicado: (2016)

High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis
por: Chandrasekar, Thenappan, et al.
Publicado: (2018)

Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy
por: Boström, Peter J., et al.
Publicado: (2016)

Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis
por: Ahmad, Ardalan E, et al.
Publicado: (2019)

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review
por: Fleshner, Neil E., et al.
Publicado: (2023)

Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine
por: Lobo, Nazleen C., et al.
Publicado: (2016)

Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial
por: Santa Mina, Daniel, et al.
Publicado: (2014)

Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
por: Clark, Roderick, et al.
Publicado: (2022)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
por: Alibhai, Shabbir M. H., et al.
Publicado: (2021)

Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
por: Wettstein, Marian S., et al.
Publicado: (2019)

Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
por: Nguyen, Linh T., et al.
Publicado: (2022)

A pilot randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence after radical prostatectomy: a study protocol
por: Santa Mina, Daniel, et al.
Publicado: (2015)

Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
por: Wettstein, Marian S., et al.
Publicado: (2020)

Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
por: Hermanns, T, et al.
Publicado: (2014)

Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis
por: Goldberg, Hanan, et al.
Publicado: (2018)

Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer
por: Navarro-Domenech, Inmaculada, et al.
Publicado: (2023)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
por: Lilge, Lothar, et al.
Publicado: (2020)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer (Erratum)
por: Lilge, Lothar, et al.
Publicado: (2020)

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
por: Alkhateeb, Sultan S., et al.
Publicado: (2011)

Optimized management in patients with bladder cancer
por: Babjuk, Marek
Publicado: (2015)

Is pathology necessary to predict mortality among men with prostate-cancer?
por: Margel, David, et al.
Publicado: (2014)

Population‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bladder cancer
por: Benidir, Tarik, et al.
Publicado: (2021)

A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence
por: Kamdar, Shivani, et al.
Publicado: (2020)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

Evaluation and management of overactive bladder: strategies for optimizing care
por: Willis-Gray, Marcella G, et al.
Publicado: (2016)

How to optimally manage elderly bladder cancer patients?
por: Soria, Francesco, et al.
Publicado: (2016)

The Value of Performance Status in Predicting Clinical Outcomes in Patients With Cancer-Associated Pulmonary Embolism
por: Papadopoulos, Efthymios, et al.
Publicado: (2022)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Risk Stratification for the Rate and Location of Residual Bladder Tumor for the Decision of Re-Transurethral Resection of Bladder Tumor
por: Fan, Junjie, et al.
Publicado: (2022)

Acute stroke management
por: Gupta, Manisha, et al.
Publicado: (2020)

Optimal management of muscle-invasive bladder cancer – a review
por: Scarpato, Kristen R, et al.
Publicado: (2015)

The optimal management of variant histology in muscle invasive bladder cancer
por: Tiwari, Raj Vikesh, et al.
Publicado: (2020)

The use of predictive models to optimize risk of decisions()
por: Baranyi, József, et al.
Publicado: (2017)

Optimal decisions under uncertainty: methods, models, and management
por: Sengupta, Jati K
Publicado: (1985)

Construction program management: decision making and optimization techniques
por: Haidar, Ali D
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vj4t9qj4bpkn31f4hoskm26sjm